ZSP Patentanwälte PartG mbB

An LLM-based method for detecting Advanced Persistent Threat (APT) and providing natural language interpretability of the detection findings, according to which unsupervised learning is performed, for statistical anomaly detection in provenance data of provenance-based systems. Large Language Models (LLMs) with implicit knowledge are used to detect unknown attack patterns by performing context-aware graph-based analysis of detected anomalies in the provenance data, for accurate interpretation of the detected anomalies and underlying context of potential attacks; natural language explanations, drawing connections between events, and outputting insights, based on the interpretation are provided.

An RL-based framework for energy efficient onboard anomaly detection of a satellite moving in a predetermined orbit, comprising a repository of pre-trained anomaly detection models, trained on a specific subset of samples, or rule-based detectors; onboard sensors for continuously monitoring the satellite systems and data network and the onboard collected data; an RL-based agent for deciding which model to activate each time and what features to monitor via a subset of sensors, according to the location, cyber vulnerability level, previous anomalous activity, functions to be executed and energy state of the battery of the satellite, to achieve in each state the highest performance of each anomaly detection task, while investing the lowest amount of energy possible; means for providing alerts in the event of a detected cyber-attack.

Systems and methods are provided for ring aperture vertical-cavity surface-emitting laser (VCSEL) devices for mode control. A VCSEL is provided where the optical mode and the current confinement is defined by patterning the same layer of the resonant cavity within the epitaxial layer with a ring-shaped aperture. The ring width may be small enough to be single mode along the radius. The two concentric boundaries forming the ring aperture may be of any arbitrary shape as long as the width is small enough to be single mode along the radial direction.

The present invention relates to combinations, pharmaceutical compositions and fusion molecules comprising an FGF21 (fibroblast growth factor 21) compound and a GLP-1R (glucagon-like peptide-1 receptor) agonist with optimized GLP-1R agonist / FGF21 compound activity ratio. It further relates to their use as medicaments, in particular for the treatment of obesity, being overweight, metabolic syndrome, diabetes mellitus, diabetic retinopathy, hyperglycemia, dyslipidemia, Non-Alcoholic SteatoHepatitis (NASH) and/or atherosclerosis.

The present invention provides a VWF fragment comprising the D' domain and D3 domain of VWF, a chimeric protein comprising the VWF fragment and a heterologous moiety, or a chimeric protein comprising the VWF fragment and a FVIII protein and methods of using the same. A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein. By preventing or inhibiting binding of endogenous VWF to the FVIII, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.

A system for a drug delivery device (1) is provided, comprising: a housing (10, 350), a cartridge unit (300), which is attachable to the housing or releasably attached to the housing, wherein the cartridge unit comprises a cartridge unit guide feature (327), the cartridge unit guide feature being provided to establish a guiding interface (327, 351) with the housing in order to guide relative movement of the cartridge unit and the housing with respect to one another when attaching the cartridge unit to the housing, and wherein the cartridge unit comprises a cartridge unit interface feature (329, 334), the cartridge unit interface feature being provided to form a further interface, in addition to the guiding interface, with the housing the further interface being established when the cartridge unit is attached to the housing, wherein the guiding interface is a bayonet-type interface which defines at least two different stages of movement between the cartridge unit and the housing when the cartridge unit is attached to the housing, a first stage (351a) with at least axial movement by a first stage axial distance in a first stage axial direction and a second stage (351b) with at least rotational movement by a second stage angle in a second stage rotational direction, and wherein the further interface is or comprises a ramp interface.

Optical amplifiers, laser devices, and methods of forming such devices are disclosed. One such method includes forming a lower cladding layer on a substrate and forming a doped ceramic layer on the lower cladding layer. The forming of the doped ceramic layer uses a plasma-assisted process that deposits and co-dopes a ceramic material with rare-earth dopants. The method also includes forming an upper cladding layer on the doped ceramic layer, and etching the upper cladding layer and the doped ceramic layer to form a doped ceramic waveguide.

A method of producing vertical silicon surfaces for mirror substrate applications is described. In some embodiments, methods as described herein may create a polishable silicon layer on a SiSiC surface.

This disclosure describes systems and methods for designing a wafer annealing chamber that combines laminar or near laminar purge gas flows across the wafer, higher flow and pressure in the upper portion of the chamber, and a specific progression of the lasing pattern relative to the purge gas laminar flow direction.

Methods and compositions for treating a subject hosting a non-ACTH-secreting pancreatic tumor are disclosed. The methods include administering to the subject a chemotherapeutic agent and a glucocorticoid receptor modulator (GRM), preferably a selective glucocorticoid receptor modulator (SGRM), to reduce the tumor load in the subject. The GRM may be a nonsteroidal GRM, and may be a nonsteroidal SGRM. The non-ACTH-secreting pancreatic tumor may be an exocrine pancreatic tumor. The nonsteroidal SGRM may be a nonsteroidal compound comprising: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure. Pharmaceutical compositions comprising a chemotherapeutic agent and a GRM are disclosed. The GRM in such pharmaceutical compositions may be a nonsteroidal GRM, and may be a SGRM, such as a nonsteroidal SGRM. The nonsteroidal SGRM may comprise: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure.